{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:14:16Z","timestamp":1790007256672,"version":"4.0.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000245","name":"Michael Smith Health Research BC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"name":"RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network","award":["192262"],"award-info":[{"award-number":["192262"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"DOI":"10.1038\/s41390-026-05138-6","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:50:23Z","timestamp":1780494623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical pharmacology insights from recent cell and gene therapy approvals relevant to pediatrics"],"prefix":"10.1038","author":[{"given":"Sahana","family":"Kunanayagam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrina M.","family":"Loucks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Facundo","family":"Garcia-Bournissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruud H. J.","family":"Verstegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2137-8339","authenticated-orcid":false,"given":"Tamorah","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"5138_CR1","unstructured":"Approved Cellular and Gene Therapy Products. Approved Cellular and Gene Therapy Products https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products (2025)."},{"key":"5138_CR2","unstructured":"Biologicals. https:\/\/www.who.int\/health-topics\/biologicals#tab=tab_1."},{"key":"5138_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120375","volume":"294","author":"N Sayed","year":"2022","unstructured":"Sayed, N. et al. Gene therapy: Comprehensive overview and therapeutic applications. Life Sci. 294, 120375 (2022).","journal-title":"Life Sci."},{"key":"5138_CR4","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1016\/j.ymthe.2023.11.001","volume":"31","author":"D Chancellor","year":"2023","unstructured":"Chancellor, D., Barrett, D., Nguyen-Jatkoe, L., Millington, S. & Eckhardt, F. The state of cell and gene therapy in 2023. Mol. Ther. 31, 3376\u20133388 (2023).","journal-title":"Mol. Ther."},{"key":"5138_CR5","unstructured":"Building a National Strategy for High-Cost Drugs for Rare Diseases: A Discussion Paper for Engaging Canadians. Building a National Strategy for High-Cost Drugs for Rare Diseases: A Discussion Paper for Engaging Canadians https:\/\/www.canada.ca\/en\/health-canada\/programs\/consultation-national-strategy-high-cost-drugs-rare-diseases-online-engagement\/discussion-paper.html (2023)."},{"key":"5138_CR6","first-page":"174","volume":"30","author":"J Posner","year":"2012","unstructured":"Posner, J. Clinical pharmacology: the basics. Surgery 30, 174\u2013180 (2012).","journal-title":"Surgery"},{"key":"5138_CR7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/cts.12615","volume":"12","author":"V Shakhnovich","year":"2019","unstructured":"Shakhnovich, V., Hornik, C. P., Kearns, G. L., Weigel, J. & Abdel-Rahman, S. M. How to Conduct clinical trials in children: a tutorial. Clin. Transl. Sci. 12, 218\u2013230 (2019).","journal-title":"Clin. Transl. Sci."},{"key":"5138_CR8","doi-asserted-by":"crossref","unstructured":"Ahmed, M. A. et al. Unlocking the mysteries of rare disease drug development: a beginner\u2019s guide for clinical pharmacologists. Clin. Transl. Sci. 18, e70215 (2025).","DOI":"10.1111\/cts.70215"},{"key":"5138_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1158\/2159-8290.CD-20-0779","volume":"11","author":"TW Laetsch","year":"2021","unstructured":"Laetsch, T. W., DuBois, S. G., Bender, J. G., Macy, M. E. & Moreno, L. Opportunities and challenges in drug development for pediatric cancers. Cancer Discov. 11, 545\u2013559 (2021).","journal-title":"Cancer Discov."},{"key":"5138_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.xphs.2023.10.005","volume":"113","author":"S Liu","year":"2024","unstructured":"Liu, S. et al. Whole-body disposition and physiologically based pharmacokinetic modeling of adeno-associated viruses and the transgene product. J. Pharm. Sci. 113, 141\u2013157 (2024).","journal-title":"J. Pharm. Sci."},{"key":"5138_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bcp.12267","volume":"79","author":"HK Batchelor","year":"2015","unstructured":"Batchelor, H. K. & Marriott, J. F. Paediatric pharmacokinetics: key considerations. Br. J. Clin. Pharm. 79, 395\u2013404 (2015).","journal-title":"Br. J. Clin. Pharm."},{"key":"5138_CR12","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1182\/bloodadvances.2024013150","volume":"8","author":"S Agarwal","year":"2024","unstructured":"Agarwal, S. et al. Blood biodistribution and vector shedding of valoctocogene roxaparvovec in people with severe hemophilia A. Blood Adv. 8, 4606\u20134615 (2024).","journal-title":"Blood Adv."},{"key":"5138_CR13","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1016\/j.apsb.2022.03.009","volume":"12","author":"Y Lai","year":"2022","unstructured":"Lai, Y. et al. Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development. Acta Pharmac, Sin. B 12, 2751\u20132777 (2022).","journal-title":"Acta Pharmac, Sin. B"},{"key":"5138_CR14","unstructured":"Zolgensma. https:\/\/www.fda.gov\/vaccines-blood-biologics\/zolgensma (2025)."},{"key":"5138_CR15","unstructured":"Kebilidi. https:\/\/www.fda.gov\/vaccines-blood-biologics\/kebilidi (2024)."},{"key":"5138_CR16","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/jimd.12247","volume":"43","author":"TS Pearson","year":"2020","unstructured":"Pearson, T. S. et al. AADC deficiency from infancy to adulthood: Symptoms and developmental outcome in an international cohort of 63 patients. J. Inherit. Metab. Dis. 43, 1121\u20131130 (2020).","journal-title":"J. Inherit. Metab. Dis."},{"key":"5138_CR17","doi-asserted-by":"crossref","unstructured":"Sun, K. & Liao, M. Z. Clinical pharmacology considerations on recombinant adeno-associated virus\u2013based gene therapy. J. Clin. Pharma. 62, S79-S94 (2022).","DOI":"10.1002\/jcph.2141"},{"key":"5138_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s12033-024-01070-4","volume":"67","author":"O Volodina","year":"2025","unstructured":"Volodina, O. & Smirnikhina, S. The future of gene therapy: a review of in vivo and ex vivo delivery methods for genome editing-based therapies. Mol. Biotechnol. 67, 425\u2013437 (2025).","journal-title":"Mol. Biotechnol."},{"key":"5138_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/1535676019899502","volume":"25","author":"S Ghosh","year":"2020","unstructured":"Ghosh, S., Brown, A. M., Jenkins, C. & Campbell, K. Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges. Appl. Biosaf. 25, 7\u201318 (2020).","journal-title":"Appl. Biosaf."},{"key":"5138_CR20","unstructured":"Beqvez. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/beqvez (2024)."},{"key":"5138_CR21","unstructured":"Hemgenix. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/hemgenix (2023)."},{"key":"5138_CR22","unstructured":"Luxturna. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/luxturna (2022)."},{"key":"5138_CR23","doi-asserted-by":"publisher","first-page":"20143085","DOI":"10.1098\/rspb.2014.3085","volume":"282","author":"AK Simon","year":"2015","unstructured":"Simon, A. K., Hollander, G. A. & McMichael, A. Evolution of the immune system in humans from infancy to old age. Proc. R. Soc. B. 282, 20143085 (2015).","journal-title":"Proc. R. Soc. B."},{"key":"5138_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.omtm.2017.12.007","volume":"8","author":"TJ Conlon","year":"2018","unstructured":"Conlon, T. J. & Mavilio, F. The pharmacology of gene and cell therapy. Mol. Ther. - Methods Clin. Dev. 8, 181\u2013182 (2018).","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"5138_CR25","unstructured":"A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants. https:\/\/clinicaltrials.gov\/study\/NCT04903288 (2025)."},{"key":"5138_CR26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ymthe.2006.04.008","volume":"14","author":"JR Forsayeth","year":"2006","unstructured":"Forsayeth, J. R. et al. A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol. Ther. 14, 571\u2013577 (2006).","journal-title":"Mol. Ther."},{"key":"5138_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/hum.2011.220","volume":"23","author":"G Mittermeyer","year":"2012","unstructured":"Mittermeyer, G. et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson\u2019s disease. Hum. Gene Ther. 23, 377\u2013381 (2012).","journal-title":"Hum. Gene Ther."},{"key":"5138_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S2352-4642(17)30125-6","volume":"1","author":"Y-H Chien","year":"2017","unstructured":"Chien, Y.-H. et al. Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1\/2 trial.  Lancet Child Adolesc. Health 1, 265\u2013273 (2017).","journal-title":"Lancet Child Adolesc. Health"},{"key":"5138_CR29","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell, J. R. et al. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurol. 78, 834\u2013841 (2021).","journal-title":"JAMA Neurol."},{"key":"5138_CR30","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S1359-6446(03)02889-7","volume":"8","author":"H Kamiya","year":"2003","unstructured":"Kamiya, H., Akita, H. & Harashima, H. Pharmacokinetic and pharmacodynamic considerations in gene therapy. Drug Discov. Today 8, 990\u2013996 (2003).","journal-title":"Drug Discov. Today"},{"key":"5138_CR31","unstructured":"Casgevy. https:\/\/www.fda.gov\/vaccines-blood-biologics\/casgevy (2024)."},{"key":"5138_CR32","unstructured":"Lenmeldy. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/lenmeldy (2025)."},{"key":"5138_CR33","unstructured":"Lyfgenia. https:\/\/www.fda.gov\/vaccines-blood-biologics\/lyfgenia (2024)."},{"key":"5138_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L. & Gao, G. Viral vector platforms within the gene therapy landscape. Sig Transduct. Target Ther. 6, 53 (2021).","journal-title":"Sig Transduct. Target Ther."},{"key":"5138_CR35","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1089\/scd.2004.13.598","volume":"13","author":"AP Jillella","year":"2004","unstructured":"Jillella, A. P. & Ustun, C. What is the optimum number of CD34+peripheral blood stem cells for an autologous transplant? Stem Cells Dev. 13, 598\u2013606 (2004).","journal-title":"Stem Cells Dev."},{"key":"5138_CR36","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul, H. et al. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-Thalassemia. N. Engl. J. Med 384, 252\u2013260 (2021).","journal-title":"N. Engl. J. Med"},{"key":"5138_CR37","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","volume":"377","author":"F Eichler","year":"2017","unstructured":"Eichler, F. et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N. Engl. J. Med 377, 1630\u20131638 (2017).","journal-title":"N. Engl. J. Med"},{"key":"5138_CR38","unstructured":"Skysona. https:\/\/www.fda.gov\/vaccines-blood-biologics\/skysona (2024)."},{"key":"5138_CR39","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","volume":"378","author":"AA Thompson","year":"2018","unstructured":"Thompson, A. A. et al. Gene Therapy in Patients with Transfusion-Dependent \u03b2-Thalassemia. N. Engl. J. Med. 378, 1479\u20131493 (2018).","journal-title":"N. Engl. J. Med."},{"key":"5138_CR40","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","volume":"6","author":"F Ferrua","year":"2019","unstructured":"Ferrua, F. et al. Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study.  Lancet Haematol. 6, e239\u2013e253 (2019).","journal-title":"Lancet Haematol."},{"key":"5138_CR41","doi-asserted-by":"publisher","first-page":"756029","DOI":"10.3389\/fmed.2021.756029","volume":"8","author":"AE-H El-Kadiry","year":"2021","unstructured":"El-Kadiry, A. E.-H., Rafei, M. & Shammaa, R. Cell therapy: types, regulation, and clinical benefits. Front Med. 8, 756029 (2021).","journal-title":"Front Med."},{"key":"5138_CR42","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1111\/cts.13349","volume":"15","author":"J Kast","year":"2022","unstructured":"Kast, J. et al. Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development. Clin. Transl. Sci. 15, 2057\u20132074 (2022).","journal-title":"Clin. Transl. Sci."},{"key":"5138_CR43","unstructured":"Human Gene Therapy for Rare Diseases. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-rare-diseases (2020)."},{"key":"5138_CR44","doi-asserted-by":"publisher","unstructured":"Tegenge, M. A., Wang, X., Liu, J., Zhu, H. & Fashoyin-Aje, L. A. FDA Experience on CAR T Cell Pharmacokinetics\/Pharmacodynamics and Model-Based Assessments. Clin. Pharma. Ther. https:\/\/doi.org\/10.1002\/cpt.3703 (2025).","DOI":"10.1002\/cpt.3703"},{"key":"5138_CR45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/cyto.b.21880","volume":"98","author":"E Maryamchik","year":"2020","unstructured":"Maryamchik, E., Gallagher, K. M. E., Preffer, F. I., Kadauke, S. & Maus, M. V. New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry. Cytom. Part B Clin. 98, 299\u2013327 (2020).","journal-title":"Cytom. Part B Clin."},{"key":"5138_CR46","doi-asserted-by":"publisher","first-page":"114421","DOI":"10.1016\/j.addr.2022.114421","volume":"188","author":"T Qi","year":"2022","unstructured":"Qi, T., McGrath, K., Ranganathan, R., Dotti, G. & Cao, Y. Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology. Adv. Drug Deliv. Rev. 188, 114421 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"5138_CR47","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/psp4.12598","volume":"10","author":"AP Singh","year":"2021","unstructured":"Singh, A. P. et al. Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: A case study with anti-BCMA CAR-T. CPT Pharm. Syst. Pharma 10, 362\u2013376 (2021).","journal-title":"CPT Pharm. Syst. Pharma"},{"key":"5138_CR48","doi-asserted-by":"crossref","unstructured":"Wang, Z. & Han, W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 6, 4 (2018).","DOI":"10.1186\/s40364-018-0116-0"},{"key":"5138_CR49","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","volume":"130","author":"KT Mueller","year":"2017","unstructured":"Mueller, K. T. et al. Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood 130, 2317\u20132325 (2017).","journal-title":"Blood"},{"key":"5138_CR50","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408\u20131414 (2019).","journal-title":"Nat. Med."},{"key":"5138_CR51","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/psp4.13011","volume":"12","author":"AM Mc Laughlin","year":"2023","unstructured":"Mc Laughlin, A. M., Milligan, P. A., Yee, C. & Bergstrand, M. Model-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic\/dynamic modeling. CPT Pharm. Syst. Pharma 12, 1577\u20131590 (2023).","journal-title":"CPT Pharm. Syst. Pharma"},{"key":"5138_CR52","unstructured":"Kymriah. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah (2025)."},{"key":"5138_CR53","unstructured":"Yescarta. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta (2025)."},{"key":"5138_CR54","unstructured":"Abecma. https:\/\/www.fda.gov\/vaccines-blood-biologics\/abecma-idecabtagene-vicleucel (2025)."},{"key":"5138_CR55","unstructured":"Carvykti. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/carvykti (2025)."},{"key":"5138_CR56","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453\u20131464 (2009).","journal-title":"Mol. Ther."},{"key":"5138_CR57","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia. N. Engl. J. Med 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med"},{"key":"5138_CR58","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia. N. Engl. J. Med 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med"},{"key":"5138_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104648","volume":"209","author":"DA Mart\u00ednez-Gamboa","year":"2025","unstructured":"Mart\u00ednez-Gamboa, D. A. et al. CAR T-cell therapy landscape in pediatric, adolescent and young adult oncology \u2013 A comprehensive analysis of clinical trials. Crit. Rev. Oncol. \/Hematol. 209, 104648 (2025).","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"5138_CR60","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1682381","volume":"9","author":"JP Sanderson","year":"2020","unstructured":"Sanderson, J. P. et al. Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy. Oncoimmunology 9, 1682381 (2020).","journal-title":"Oncoimmunology"},{"key":"5138_CR61","unstructured":"Tecelra. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecelra (2024)."},{"key":"5138_CR62","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.tips.2015.11.004","volume":"37","author":"DT Harris","year":"2016","unstructured":"Harris, D. T. & Kranz, D. M. Adoptive T cell therapies: a comparison of t cell receptors and chimeric antigen receptors. Trends Pharm. Sci. 37, 220\u2013230 (2016).","journal-title":"Trends Pharm. Sci."},{"key":"5138_CR63","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jcyt.2024.08.002","volume":"27","author":"J Metts","year":"2025","unstructured":"Metts, J. et al. Expansion of tumor-infiltrating and marrow-infiltrating lymphocytes from pediatric malignant solid tumors. Cytotherapy 27, 29\u201335 (2025).","journal-title":"Cytotherapy"},{"key":"5138_CR64","unstructured":"Amtagvi. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/amtagvi (2024)."},{"key":"5138_CR65","unstructured":"Ryoncil. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/ryoncil (2025)."},{"key":"5138_CR66","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.bbmt.2020.01.018","volume":"26","author":"J Kurtzberg","year":"2020","unstructured":"Kurtzberg, J. et al. A Phase 3, single-arm, prospective study of Remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. Biol. Blood Marrow Transpl. 26, 845\u2013854 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"5138_CR67","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11010-020-03834-3","volume":"474","author":"R Tang","year":"2020","unstructured":"Tang, R. & Xu, Z. Gene therapy: a double-edged sword with great powers. Mol. Cell Biochem 474, 73\u201381 (2020).","journal-title":"Mol. Cell Biochem"},{"key":"5138_CR68","doi-asserted-by":"publisher","DOI":"10.1172\/JCI177078","volume":"134","author":"EM McNally","year":"2024","unstructured":"McNally, E. M. Improving the safety of systemic viral gene therapy. J. Clin. Invest 134, e177078 (2024).","journal-title":"J. Clin. Invest"},{"key":"5138_CR69","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. Immunother. Cancer 6, 56 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"5138_CR70","doi-asserted-by":"crossref","unstructured":"Kirouac, D. C., Zmurchok, C. & Morris, D. Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics. npj Syst. Biol. Appl. 10, 31 (2024).","DOI":"10.1038\/s41540-024-00355-3"},{"key":"5138_CR71","unstructured":"Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal (2020)."},{"key":"5138_CR72","unstructured":"Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-development-chimeric-antigen-receptor-car-t-cell-products (2024)."},{"key":"5138_CR73","unstructured":"Guidance documents: Biologics, radiopharmaceuticals, cell and gene therapies. Guidance documents: Biologics, radiopharmaceuticals, cell and gene therapies https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/biologics-radiopharmaceuticals-genetic-therapies\/applications-submissions\/guidance-documents.html."},{"key":"5138_CR74","unstructured":"Guidelines relevant for advanced therapy medicinal products. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/advanced-therapy-medicinal-products-overview\/guidelines-relevant-advanced-therapy-medicinal-products."},{"key":"5138_CR75","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/psp4.12764","volume":"11","author":"TN Johnson","year":"2022","unstructured":"Johnson, T. N., Small, B. G. & Rowland Yeo, K. Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations. CPT Pharmacomet. Syst. Pharm. 11, 373\u2013383 (2022).","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"5138_CR76","doi-asserted-by":"publisher","first-page":"107541","DOI":"10.1016\/j.pharmthera.2020.107541","volume":"211","author":"LFM Verscheijden","year":"2020","unstructured":"Verscheijden, L. F. M., Koenderink, J. B., Johnson, T. N., De Wildt, S. N. & Russel, F. G. M. Physiologically-based pharmacokinetic models for children: Starting to reach maturation? Pharmacol. Ther. 211, 107541 (2020).","journal-title":"Pharmacol. Ther."},{"key":"5138_CR77","doi-asserted-by":"publisher","first-page":"20201013","DOI":"10.1098\/rsif.2020.1013","volume":"18","author":"LV Brown","year":"2021","unstructured":"Brown, L. V., Gaffney, E. A., Ager, A., Wagg, J. & Coles, M. C. Quantifying the limits of CAR T-cell delivery in mice and men. J. R. Soc. Interface 18, 20201013 (2021).","journal-title":"J. R. Soc. Interface"},{"key":"5138_CR78","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.ads0252","volume":"385","author":"RH Rouce","year":"2024","unstructured":"Rouce, R. H. & Porteus, M. H. Cell and gene therapy accessibility. Science 385, 475\u2013475 (2024).","journal-title":"Science"},{"key":"5138_CR79","unstructured":"Pfizer halts Hemophilia B gene therapy. https:\/\/www.bleeding.org\/news\/pfizer-discontinues-beqvez-hemophilia-b-gene-therapy (2025)."},{"key":"5138_CR80","unstructured":"Opportunities lie with Beqvez Discontinutation. https:\/\/blogs.bmj.com\/medical-ethics\/2025\/04\/03\/opportunities-lie-within-beqvezs-discontinuation\/ (2025)."},{"key":"5138_CR81","unstructured":"Biorender. https:\/\/BioRender.com."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05138-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05138-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05138-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:02:53Z","timestamp":1780498973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05138-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":81,"alternative-id":["5138"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-05138-6","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}